NASDAQ:BMRA Biomerica - BMRA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.87 0.00 (0.00%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.86▼$2.8850-Day Range$2.80▼$3.8852-Week Range$2.56▼$5.25Volume11,259 shsAverage Volume29,483 shsMarket Capitalization$38.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Biomerica (NASDAQ:BMRA) StockBiomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.Read More Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRA Stock News HeadlinesJanuary 10, 2023 | finance.yahoo.comBiomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory BoardJanuary 10, 2023 | finance.yahoo.comBiomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory BoardFebruary 9, 2023 | Masterworks (Ad)A step-by-step guide to Investing Outside the Stock Market.Experts from BofA to Blackrock agree: the 60-40 asset allocation model is outdated. With equity forecasts at historic lows, top portfolio managers are turning to alternative assets like fine art to potentially enhance returns. Fine art is a $1.7 trillion-dollar asset class that's outpaced the S&P 500 by more than 2x in the last 25 years. With Masterworks, it's easy for anyone to invest in art. Get started today with a special link. **See important disclosures December 24, 2022 | seekingalpha.comBiomerica: H.Pylori Announcements Important To Keep An Eye On, Reaffirm HoldDecember 8, 2022 | finance.yahoo.comBiomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAEDecember 1, 2022 | finance.yahoo.comWe Think Shareholders May Consider Being More Generous With Biomerica, Inc.'s (NASDAQ:BMRA) CEO Compensation PackageOctober 17, 2022 | finanznachrichten.deBiomerica, Inc.: Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022October 14, 2022 | finance.yahoo.comSneakerheads Will Be Happy: Nike Is Ready to Penalize Accounts Reselling Its Products - Yahoo FinanceFebruary 9, 2023 | Vantage Point (Ad)3 Secrets To Consistent Trading SuccessDon't get caught in the trap of standing on the sidelines of intermarket correlation. The truth is that it’s impossible for you (or any human) to visualize and calculate complicated intermarket causations. Learn with A.I. which global markets have the most influence on a target market. Save a Seat for This Free Live Training. October 14, 2022 | seekingalpha.comAvenue, IMARA lead healthcare gainers; Galecto, Travere among losers - Seeking AlphaOctober 14, 2022 | marketwatch.comBiomerica stock leaps as Walmart expands sales of Aware Breast Self Exam to its stores - MarketWatchOctober 14, 2022 | finance.yahoo.comBiomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 - Yahoo FinanceOctober 13, 2022 | globenewswire.comBiomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 - GlobeNewswireOctober 13, 2022 | finance.yahoo.comBiomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022October 11, 2022 | finance.yahoo.comThose who invested in Biomerica (NASDAQ:BMRA) five years ago are up 39%September 30, 2022 | it.tmcnet.comBiomerica's Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by AmazonSeptember 29, 2022 | benzinga.comThinking about buying stock in BigBear.ai, Bed Bath & Beyond, Atara Biotherapeutics, Stabilis Solutions, - BenzingaSeptember 29, 2022 | benzinga.comBiomerica's Aware Breast Self Exam and EZ Detect Colon Disease Test Now Available On Amazon And Fulfilled - BenzingaSeptember 29, 2022 | finance.yahoo.comBiomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by AmazonSeptember 26, 2022 | globenewswire.comBlood Testing Market to hit USD 123 Billion by 2030, says Global Market Insights Inc. - GlobeNewswireSeptember 14, 2022 | globenewswire.comLifeMD Expands Primary Care Platform's Diagnostic - GlobeNewswireSeptember 9, 2022 | seekingalpha.comBiomerica: One To Watch Closely For The Future, But From The Sidelines For NowSeptember 5, 2022 | nasdaq.comBiomerica (NASDAQ:BMRA) Is In A Strong Position To Grow Its Business - NasdaqSeptember 2, 2022 | seekingalpha.comBright Minds, PaxMedica top healthcare gainers; PolyPid, Shuttle lead losers' pack - Seeking AlphaAugust 31, 2022 | finance.yahoo.comWe're Interested To See How Biomerica (NASDAQ:BMRA) Uses Its Cash Hoard To GrowAugust 30, 2022 | finance.yahoo.comBiomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer - Yahoo FinanceAugust 30, 2022 | globenewswire.comBiomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRA Company Calendar Last Earnings1/13/2022Today2/09/2023Next Earnings (Estimated)4/13/2023Fiscal Year End5/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BMRA CUSIPN/A CIK73290 Webwww.biomerica.com Phone(949) 645-2111Fax949-553-1231Employees66Year Founded1971Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,530,000.00 Net Margins-34.58% Pretax Margin-34.48% Return on Equity-66.11% Return on Assets-44.58% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio3.42 Sales & Book Value Annual Sales$18.87 million Price / Sales2.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book4.42Miscellaneous Outstanding Shares13,480,000Free Float11,363,000Market Cap$38.69 million OptionableNot Optionable Beta-0.57 Social Links Key ExecutivesZackary S. IraniChairman & Chief Executive OfficerSteve SloanChief Financial Officer & TreasurerRobert CarlsonChief Commercial OfficerKey CompetitorsNymox PharmaceuticalNASDAQ:NYMXTrinity BiotechNASDAQ:TRIBOncoCyteNASDAQ:OCXARCA biopharmaNASDAQ:ABIOImmuCellNASDAQ:ICCCView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Bought 32,061 shares on 2/8/2023Ownership: 0.473%Hollencrest Capital ManagementBought 50,000 shares on 2/7/2023Ownership: 0.371%Simplex Trading LLCSold 2,400 shares on 2/2/2023Ownership: 0.000%Allen BarbieriBought 1,538 shares on 1/27/2023Total: $4,521.72 ($2.94/share)Catherine CosteBought 2,190 shares on 1/26/2023Total: $6,482.40 ($2.96/share)View All Insider TransactionsView All Institutional Transactions BMRA Stock - Frequently Asked Questions Should I buy or sell Biomerica stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BMRA shares. View BMRA analyst ratings or view top-rated stocks. How have BMRA shares performed in 2023? Biomerica's stock was trading at $3.35 on January 1st, 2023. Since then, BMRA stock has decreased by 14.3% and is now trading at $2.87. View the best growth stocks for 2023 here. Are investors shorting Biomerica? Biomerica saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 397,200 shares, a decline of 8.1% from the December 31st total of 432,300 shares. Based on an average trading volume of 28,000 shares, the short-interest ratio is presently 14.2 days. Approximately 3.5% of the shares of the stock are sold short. View Biomerica's Short Interest. When is Biomerica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 13th 2023. View our BMRA earnings forecast. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) posted its earnings results on Thursday, January, 13th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The company had revenue of $4.65 million for the quarter. Biomerica had a negative net margin of 34.58% and a negative trailing twelve-month return on equity of 66.11%. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN). What is Biomerica's stock symbol? Biomerica trades on the NASDAQ under the ticker symbol "BMRA." Who are Biomerica's major shareholders? Biomerica's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.47%), Hollencrest Capital Management (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste, Mark A Sirgo and Zackary S Irani. View institutional ownership trends. How do I buy shares of Biomerica? Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biomerica's stock price today? One share of BMRA stock can currently be purchased for approximately $2.87. How much money does Biomerica make? Biomerica (NASDAQ:BMRA) has a market capitalization of $38.69 million and generates $18.87 million in revenue each year. The company earns $-4,530,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. How can I contact Biomerica? Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The official website for the company is www.biomerica.com. The company can be reached via phone at (949) 645-2111, via email at jnesbett@institutionalms.com, or via fax at 949-553-1231. This page (NASDAQ:BMRA) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.